Bio-Techne (MIL:1TECH) Other Current Receivables: €0 Mil (As of Mar. 2026)


MIL:1TECH Bio-Techne Corp MIL:1TECH
59 GF Score
Price €62.06
GF Value €77.15
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Bio-Techne Other Current Receivables?

Bio-Techne MIL:1TECH 59 Other Current Receivables is €0 Mil as of Mar. 2026. GuruFocus rates MIL:1TECH with a GF Score™ of 59/100 and a GF Value™ of €77.15 (Modestly Undervalued). The stock has 8 warning signs investors should review.

Bio-Techne's Other Current Receivables for the quarter that ended in Mar. 2026 was €0 Mil.

Bio-Techne Other Current Receivables Related Terms

Bio-Techne Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Bio-Techne's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Techne Other Current Receivables Chart

Bio-Techne Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Bio-Techne Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MIL:1TECH
59GF Score
Bio-Techne Corp MIL:1TECH
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bio-Techne Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of €0 Mil mean?
Bio-Techne (MIL:1TECH) has a Other Current Receivables of €0 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Bio-Techne and its competitors.
Is Bio-Techne's Other Current Receivables too high?
Bio-Techne's current Other Current Receivables is €0 Mil. Overall, Bio-Techne has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bio-Techne's Other Current Receivables compare to ARWR and CYTK?
Bio-Techne's Other Current Receivables of €0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Bio-Techne and its competitors. Bio-Techne's current Other Current Receivables is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Techne stock overvalued right now?
Based on GuruFocus' analysis, Bio-Techne (MIL:1TECH) is currently considered Modestly Undervalued. The stock's GF Value™ is €77.15, compared to a current price of €62.06 — trading 19.6% below its estimated fair value. The current Other Current Receivables is €0 Mil. Bio-Techne's overall GF Score™ is 59/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Bio-Techne (MIL:1TECH), the current Other Current Receivables is €0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bio-Techne (MIL:1TECH) Overvalued in 2026?

Based on GuruFocus' analysis, Bio-Techne stock appears to be undervalued. The current stock price of €62.06 is trading 19.6% below its estimated GF Value™ of €77.15. GuruFocus considers Bio-Techne to be Modestly Undervalued.

Key valuation signals for MIL:1TECH:

  • Other Current Receivables: €0 Mil
  • GF Value™: €77.15 vs. price of €62.06 (19.6% below fair value)
  • GF Score™: 59/100 with 8 warning signs

No single metric tells the full story. See the MIL:1TECH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bio-Techne Business Description

Address 614 McKinley Place N.E., Minneapolis, MN, USA, 55413
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
59GF Score

Get the complete analysis for MIL:1TECH

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€62.06
Price
€77.15
GF Value